Trial Profile
CLADQoL: CLADribine tablets –evaluation of Quality of Life - CLADQoL
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2020
Price :
$35
*
At a glance
- Drugs Cladribine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms CLADQoL
- Sponsors Merck Serono
- 02 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 01 May 2020 Results (n=67) presented at the 72nd Annual Meeting of the American Academy of Neurology
- 28 Aug 2019 According to an Merck & Co Media release, data from this study will be presented at the 35th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS).